The miR-196a SNP Rs11614913 but not the miR-499 rs37464444 SNP is a Risk Factor for Non-small Cell Lung Cancer in an Iranian Population

Neda K. Dezfuli 1, 2, 3, Ian M. Adcock 4, Shamila D. Alipoor 5, Babak Salimi 6, Sharareh Seifi 6, Mohammad Chehrazi 7, Mohammad Varahram 2, Esmaeil Mortaz 2,3,6

Background: Globally, lung cancer represents a major cause of cancer-related deaths. The regulation of gene expression is modulated by small noncoding RNAs called miRNAs that can act as both tumor suppressors and oncogenes. The maturation, expression and binding to target mRNAs is affected by single nucleotide polymorphisms (SNPs) in miRNA genomic regions thereby contributing to cancer susceptibility. SNPs Rs11614913 in miR196a and Rs3746444 in miR-499 are implicated in the development of cancers such as non-small cell lung cancer (NSCLC) in non-Arabic subjects.

Materials and Methods: A small cohort of 204 participants including 104 lung cancer patients and 100 non-cancer controls subjects were enrolled into the study. The allele frequencies were determined by Polymerase Chain Reaction–Restriction Fragment Length Polymorphism (PCR-RFLP) and their correlation with lung cancer risk was determined.

Results: The miR-196a rs11614913 polymorphism increased the risk of NSCLC (CC vs. TT+TC: OR= 2.26, 95%CI= 1.28 – 3.98, P= 0.0046) in a dominant genetic model. No statistically significant association was found between the miR -499 rs37464444 polymorphism and NSCLC.

Conclusion: The rs11614913 polymorphism in miR-196a, but not the miR-499 rs37464444 polymorphism, increased the risk of NSCLC. Further studies with larger sample sizes in correlation with functional outcomes at the cellular level should be undertaken.

Key words: rs11614913, miR196a; rs3746444; miR-499; Lung Cancer; NSCLC

INTRODUCTION

Lung cancer is currently the commonest cancer worldwide and has a poor prognosis being associated with very high mortality rates. Lung cancer is divided broadly into two main subtypes: small-cell (SCLC) and non-small-cell lung carcinoma (NSCLC). NSCLC accounts for 80-85% of all lung cancer cases whilst SCLC includes 12% of lung cancer cases particularly those with a high mortality (1, 2). Despite recent advances in the diagnosis and therapies available, lung cancer is still a major cause of death
worldwide (3). Understanding the molecular pathology of lung cancer is critical for obtaining early diagnosis and thereby enabling initiation of timely and effective therapies.

Although smoking is recognized as the major risk factor for the development of lung cancer, the disease also occurs in nonsmokers (4). Thus, genetics and lifestyle characteristics including diet, smoking and exposure to other environmental pollutants are important factors in the susceptibility and development of lung cancer (5). Inherited familiar gene changes in P53, Myc and breast cancer gene (BRCA)1 have been described in lung cancer (1,6).

Noncoding small RNAs (ncRNA) are key factors in the development and progression of lung cancer (7). MicroRNAs are members of the small ncRNA family and act post-transcriptionally to modulate gene expression (8). MicroRNAs regulate various biological functions and may act to control the expression of oncogenes and/or tumor suppressors (8). Dysregulation of miRNA expression provokes cancer invasion, metastasis and angiogenesis (8). MicroRNA networks coordinately modulate numerous genes in the body (2,7). A SNP occurs in just under every 300bp of the genome including the coding and non-coding regions (9). However, most (93%) of SNPs that affect miRNA function are distributed within non-coding regions (10) and it is well known that SNPs associated with cancer susceptibility (2). The induction of the single nucleotide polymorphisms (SNPs) at a specific site, especially in non-coding regions, affects the induction and maturation of miRNAs in cancer (8). For example, miRNA 196a rs11614913 T/C and the miR-499 rs3746444 A/G polymorphisms are associated with the development of breast (11,12), lung (13-15), gastric (16), esophageal (17), hepatocellular (18), head and neck (19) and colorectal (20,21) cancers.

We hypothesize that polymorphisms within these miRNAs vary according to the ethnicity and geographical area of the patient. Thus, in this study we aimed to assess the possible association between miR-499 rs3746444, miR-196a rs11614913SNP in Iranian NSCLC patients.

**MATERIALS AND METHODS**

**Patients**

One hundred and four patients with newly diagnosed based on pathology and clinical manifestation of NSCLC at age 58.1 ± 8.0 years old (mean ± SD) were recruited at the Masih Daneshvari hospital (Tehran, Iran) between April 2015 and September 2019. One hundred age- and gender-matched healthy controls subjects with a negative history of cancer and other inflammatory diseases were also enrolled in the study. The Ethics Committee of the Dr. Masih Daneshvari Hospital approved the study and all subjects gave written informed consent (Ethics committee approval number: IR.SBMU.MSP.REC.1397.525).

**Genotyping**

2 ml whole blood was collected into EDTA-containing tubes from all participants and genomic DNA isolated using a DNA High Pure PCR Template Preparation Kit, (Mannheim, Roche, Germany, Version 20, Cat.No.11796828001) as described by the manufacturer. The DNA concentration was measured by Nanodrop 2000 (Thermo Fisher, MA, USA). Specific SNPs were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) with the PCR reaction performed using Taq DNA polymerase master mix (Invitrogen, Massachusetts USA), in a thermal cycler (Bio-Rad, California, USA). The primer sequences for each PCR reaction are shown in Table 1. PCR cycles were as follows: initial denaturation at 95°C for 5 min, 35 cycles of denaturation at 94°C for 30 sec, annealing at 58°C for 1 min and extension at 72°C for 1 min and a final extension at 72°C for 10 min.

To identify the mir-196 C/T polymorphism, the PCR product was digested with the restriction enzyme Taal (Thermo Fisher, USA) by incubating the samples at 65°C for 4h. The mir-499 T/C polymorphism PCR product was incubated at 37°C for 4h with the restriction enzyme.
TSP45I (Thermo Fisher, USA) and the digestion products were detected by 3% agarose gel electrophoresis.

**Statistical Analysis**

The differences in genotype distribution for the two analyzed SNPs between patients and healthy subjects were analyzed using Chi-square test. All statistical analyses were carried out using SPSS-25 software (SPSS, Inc.). P values <0.05 were considered statistically significant.

**RESULTS**

The demographic information of participants including histological subtype, stage and smoking status are demonstrated in Table 2. 104 NSCLC patients and 100 healthy controls were enrolled in this study with mean age of 58.1 and 51.7 years, respectively (Table 2).

For rs11614913 of miR196 the uncut PCR product size was 431bp and digested products shows bands at 281 and 150bp (Table 1, Figure 1A). The PCR product size for rs3746444 of miR499 was 302bp and the digested products showed bands of 111 and 191bp (Table 1, Figure 1B). The allele frequencies for rs11614913 and rs3746444 in patient and control groups are indicated in Table 3. The CC genotype of mir-196a rs11614913 was associated with an increased risk of lung cancer using a dominant genotype model (CC vs. TT+TC: OR= 2.26, 95%CI= 1.28 – 3.98, P= 0.0046). In contrast, the mir-499 rs3746444 variant was not associated with NSCLC in any inheritance model tested (Table 3).

| Table 1. PCR primer sequences and expected fragment sizes. |
|----------------------------------------------------------|
| **Polymorphism** | **Primer sequence** | **Restriction Enzyme** | **Product size (bp)** |
| Rs11614913 | F: 5’-CGGGGCTGAATTTCTTCCTTG -3’  
R: 5’-GCTGGACCCCTTTGTCTGT -3’ | Taal | Uncut product: 431  
C Allele: 431  
T Allele: 150 + 281 |
| Rs3746444 | F: 5’-GTCTTCACTTCCCTGCCAAAT -3’  
R: 5’-GAAGCGTAAGAAGGCAGCATC -3’ | TSP45I | Uncut product: 302  
T Allele: 302  
C Allele: 111 + 191 |

| Table 2. Demographic details of study participants. |
|--------------------------------------------------|
| **Factors** | **Lung cancer patients (104 subjects) n (%)** | **Control subjects (100 subjects) n (%)** |
| Age Mean±SD (Years) | 58.1 ± 8.0 | 51.7 ± 8.4 |
| Gender | Male 81 (77.8) | 80 (80) |
| Histological subtype | ADC 87 (83.6) | LCC 3 (2.8) |
| | SCC 14 (13.4) | |
| Stage | I 3 (2.8) | II 13 (12.5) |
| | III 20 (19.2) | IV 68 (65.3) |
| Smoking status | Smoker 64 (61.5) | 64 (64) |
| | Non-Smoker 40 (38.4) | 36 (36) |
Table 3. Genotypic and allelic frequencies of miR-499 rs3746444, miR-196a2 rs11614913 polymorphisms in participants.

| Polymorphism | NSCLC (104 subjects) n (%) | Control (100 subjects) n (%) | OR (95% CI) | P-value |
|--------------|-----------------------------|-----------------------------|-------------|---------|
| miR-196a2 rs11614913 C > T |                             |                             |             |         |
| Allele       |                             |                             |             |         |
| T            | 64 (30.7)                   | 82 (41)                     | 1 (reference) | 0.031   |
| C            | 144 (69.2)                  | 118 (59)                    | 1.56 (1.04 - 2.35) |         |
| Codominant   |                             |                             |             |         |
| TT           | 16 (15.3)                   | 16 (15)                     | 1 (reference) | 0.28    |
| CT           | 32 (30.7)                   | 50 (50)                     | 0.64 (0.28 - 1.45) |         |
| CC           | 56 (53.8)                   | 34 (34)                     | 1.64 (0.73 - 3.71) | 0.22    |
| Dominant     |                             |                             |             |         |
| CT+TT        | 48 (46.1)                   | 66 (66)                     | 1 (reference) |         |
| CC           | 56 (53.8)                   | 34 (34)                     | 2.26 (1.28 - 3.98) | 0.0046  |
| Recessive    |                             |                             |             |         |
| TT           | 16 (15.3)                   | 16 (15)                     | 1 (reference) | 0.9     |
| CC+CT        | 88 (84.6)                   | 84 (84)                     | 1.04 (0.49 - 2.22) |         |
| miR-499 rs3746444 T > C |                             |                             |             |         |
| Allele       |                             |                             |             |         |
| T            | 150 (72.1)                  | 148 (74)                    | 1 (reference) | 0.66    |
| C            | 58 (27.8)                   | 52 (26)                     | 1.10 (0.71 - 1.70) |         |
| Codominant   |                             |                             |             |         |
| TT           | 54 (51.9)                   | 54 (54)                     | 1 (reference) | 0.86    |
| TC           | 42 (40.3)                   | 40 (40)                     | 1.05 (0.59 - 1.86) |         |
| CC           | 8 (7.6)                     | 6 (6)                       | 1.33 (0.43 - 4.1) | 0.61    |
| Dominant     |                             |                             |             |         |
| TT+TC        | 54 (51.9)                   | 54 (54)                     | 1 (reference) | 0.76    |
| TC+CC        | 50 (48.07)                  | 46 (46)                     | 1.08 (0.62 - 1.88) |         |
| Recessive    |                             |                             |             |         |
| TT+TC        | 96 (92.3)                   | 94 (94)                     | 1 (reference) | 0.63    |
| CC           | 8 (7.6)                     | 6 (6)                       | 1.3 (0.43 - 3.9) |         |

OR = Odds Ratio.

Figure 1. Representative PCR-RFLP gels. (A) miR-196 PCR products and genotypes. Lane 1 shows the CT genotype (bands at 431, 281 and 150bp); lanes 2, 3 and 4 show the CC genotype (band at 431bp); Lanes 5 and 6 show the TT genotype (bands at 281 and 150bp) and lane 7 is the 50bp DNA ladder. (B) miR-499 PCR products and genotypes. Lanes 1, 5, 6 and 7 show the TT genotype (band at 302bp); Lanes 2 and 4 show the CT genotype (bands at 302, 191 and 111bp); lane 3 shows the CC genotype (bands at 191 and 111bp) and Lane 8 is the 100bp DNA ladder with specific size markers labelled.
Rs3746444 variants were not associated with smoking status (Table 4) whereas the CC genotype frequency in smoking patients was higher than in smoking control subjects with the rs11614913 variant (OR=2.82, 95%CI=1.01-7.83, P=0.045) (Table 4).

In addition, the C allele frequency of the rs11614913 variant correlated with stage II and III NSCLC (OR=0.09, 95%CI=0.012-0.67, P=0.019 and OR=0.14, 95%CI=0.02-0.92, P=0.041, respectively). There was no association between the rs3746444 SNP and disease stage (Table 5).

Moreover, the rs11614913 SNP in miR196 was not associated with types of NSCLC disease, however, the C allele frequency in rs3746444 of miR499 variant was higher in the large cell carcinoma (LCC) subtype (OR=0.06, 95%CI=0.007-0.59, p=0.015) (Table 5).

**Table 4. The association between SNPs and the risk of NSCLC stratified by smoking**

| Gene     | SNP       | Non-Smokers | Smokers | Adjusted OR (95%CI) | P Value |
|----------|-----------|-------------|---------|---------------------|---------|
|          |           | Control (n) | Case (n) | OR (95%CI)          |         |
| miR-196a | TT        | 3           | 8       | 1                   |         |
|          | TC        | 22          | 16      | 0.27 (0.06-1.19)    | 0.89    |
|          | CC        | 11          | 16      | 0.54 (0.11-2.52)    | 0.045   |
| miR-499  | TT        | 18          | 23      | 1                   |         |
|          | TC        | 16          | 12      | 0.58 (0.22-1.54)    | 0.31    |
|          | CC        | 2           | 5       | 1.95 (0.33-11.2)    | 0.86    |

**Table 5. Association between SNPs with stage and subtypes of lung cancer**

| Variable | rs11614913 T/C |          |          |          | Adjusted OR (95%CI) | P Value |
|----------|----------------|----------|----------|----------|---------------------|---------|
| MiR-196a |                | TT       | TC       | CC       | Allele T frequency |         |
| Stage I  | (n=3)          | 2        | 0        | 1        | 4                   | 2       |
| Stage II | (n=13)         | 1        | 2        | 10       | 4                   | 22      |
| Stage III| (n=20)         | 0        | 9        | 11       | 9                   | 31      |
| Stage IV | (n=60)         | 13       | 21       | 34       | 47                  | 89      |
| ADC Type | (n=87)         | 12       | 28       | 47       | 52                  | 122     |
| SCC Type | (n=14)         | 3        | 4        | 7        | 10                  | 18      |
| LCC Type | (n=3)          | 1        | 0        | 2        | 2                   | 4       |
| MiR-499  |                | TT       | TC       | CC       | Allele T frequency |         |
| Stage I  | (n=3)          | 1        | 2        | 0        | 4                   | 2       |
| Stage II | (n=13)         | 5        | 8        | 0        | 18                  | 8       |
| Stage III| (n=20)         | 8        | 8        | 4        | 24                  | 16      |
| Stage IV | (n=68)         | 40       | 24       | 4        | 104                 | 32      |
| ADC Type | (n=87)         | 49       | 32       | 6        | 130                 | 44      |
| SCC Type | (n=14)         | 5        | 9        | 0        | 19                  | 9       |
| LCC Type | (n=3)          | 0        | 1        | 2        | 1                   | 5       |
DISCUSSION

The current study reports that the miR-196a2 rs11614913 polymorphism, but not the miR-499 rs3746444 polymorphism, was significantly associated with Iranian NSCLC patients. In addition, there was an association of the rs11614913 polymorphism with the CC genotype in smoking NSCLC patients and of the rs11614913 C allele frequency with stage II and III disease. There was also a higher frequency of the rs3746444 C allele in LCC patients.

Previous studies reported that the rs11614913 polymorphism is associated with increased risk of lung cancer (13, 15). Meta-analysis of published studies reported that the rs11614913 polymorphism was associated with an increased risk of lung cancer particularly in Asian populations (15, 22). In our study, the rs11614913 polymorphism did not show any association with the types of NSCLC disease. Little information is available in Iranian NSCLC patients regarding miRNA polymorphisms although one study from North-East Iran also failed to find any significant association between the miR-196a2 rs11614913 polymorphism and lung cancer (23). This discrepancy between our study and the one from North-East Iran of similar size may be due to practical reasons such as usage of different enzymes, different participants from the two regions and type of NSCLC. Thus, larger, multi-centred studies across Iran using the same standardised methodology are required to confirm the role of the rs11614913 polymorphism in NSCLC patients in Iran.

The CC genotype of rs11614913, which significantly increased the expression of the mature miR-196a, was associated with decreased survival of NSCLC patients (13). Furthermore, individuals carrying the TC or CC genotype of rs11614913 had an increased risk of lung cancer compared to those possessing the TT genotype among Chinese non-smoking females (14). In addition, miR-196a2 rs11614913 variant homozygote CC was associated with approximately 25% significantly increased risk of lung cancer in the Chinese population (24). Yoon and et al. reported that the rs11614913 genetic variant positively correlated with a better recurrence-free survival (RFS) in stage II and stage III of lung cancer. Overall, these findings indicated that the rs11614913 polymorphism is strongly associated with prognosis in NSCLC patients who undergo lung resection (25).

Moreover, the rs11614913 genotypes were significantly associated with overall survival (OS) and disease-free survival (DFS) in women and in patients with stage II+IIIA disease, but not in men and patients with stage I disease (26). However, there was no difference in genotype-related adjusted hazard ratios (aHR) between the different subgroups of NSCLC (26). In contrast, the CC genotype in rs11614913 was associated with lower survival compared with TT/CT genotypes in NSCLC patients (13).

In addition, the C allele frequency in rs11614913 was higher in stage II and III NSCLC in the current study. Importantly, a previous study has shown that the TC vs. TT genotype of rs11614913 is protective for NSCLC and may reduce the risk of NSCLC in the non-SCC subgroup (27). Furthermore, an earlier study reported a significant association between the miR-196a2 rs11614913 (CT/TT) genotype with NSCLC patients who are active smokers in a Korean population (28). Our data also showed that the rs11614913 polymorphism was associated with the CC genotype in smoker patients.

The rs11614913 polymorphism is also associated with other cancers such as head and neck (19), hepatocellular (22) and breast cancers (29). The presence of any variant allele was associated with a significantly reduced risk of HNSCC but homozygous variant allele carriers with pharyngeal tumors had significantly reduced survival compared to wild-type and heterozygous forms (19). Moreover, the CC polymorphic genotype demonstrated associated with a decreased risk of breast cancer and the presence of the T allele was significantly associated with an increased risk of breast cancer (29). The functional SNP rs3746444 T/C within the miR499 gene causes an A/G transition in the mature miR-499 (13).

The ethnic background of patients with the miR-499 rs3746444 polymorphisms may affect its impact on the
susceptibility to lung cancer. The rs3746444 polymorphism is associated with decreased expression of miR-499 and poor survival in Chinese lung cancer patients (30). In contrast, Hau Qiu and co-workers found that the miR-499a rs3746444 genotypic distribution was not different in NSCLC cases and controls but this polymorphism elevated the susceptibility of NSCLC in a never smoking subgroup (adjusted $P=0.035$ for GG vs. AA genetic model and adjusted $P=0.049$ for GG vs. AA/AG genetic model) (27). Furthermore, Serena Vinci and colleagues did not find any association between miR-499 genotype and risk of NSCLC in 101 Italian NSCLC patients (31). A meta-analysis showed no association of the rs3746444 polymorphism and lung cancer in East Asian populations (32). However, another meta-analysis has shown an association between the microRNA-499 rs3746444 A/G polymorphism and cancer susceptibility in Asians, but not in Caucasians (33).

Subgroup analysis of other cancer types, demonstrated no risk of breast, liver, or lung cancers with the microRNA-499 rs3746444 A/G polymorphism (33). An association between miR-499 rs3746444 and the susceptibility to cervical squamous cell carcinoma, prostate cancer, hepatocellular carcinoma (34), chronic obstructive pulmonary disease (35) and colorectal cancer has been reported (36). The G Allele of rs3746444 was also shown to be associated with the decreased risk of prostate cancer progression in a Serbian population (37). In addition, miR-499 rs3746444 increased the risk of cancer (38) but not for breast cancer (20, 39, 40). In another study, the rs3746444 G allele was associated with an increased cancer risk factor in Chinese subjects especially for breast cancer (41). This discrepancy may be due to difference in ethnic background, since, there was a significant association of rs3746444 with the susceptibility to cancers in Asians (12, 42, 43) but not in Caucasians (44). Hashemi and colleagues have shown that the miR-499 rs3746444 polymorphism increased the risk of prostate cancer in an Iranian population (45) whilst the rs3746444 T>C polymorphism was associated with high prevalence of cancer in Iranian and Chinese populations but low prevalence with esophageal cancer (44).

There are some limitations in our study. First, this is a single center retrospective study. Due to the untimely COVID-19 epidemic, the sample size was small and lacked longitudinal samples. Future studies should include multi-centre studies across Iran and other middle eastern countries with different stages of NSCLC stages to verify these results. In addition, it will be important examine the functional impacts on the survival of NSCLC patients.

**CONCLUSION**

In conclusion, the current study data suggests an ethnic difference in the impact of rs3746444 T/C polymorphism in NSCLC lung cancer incidence. Our findings proposed that miR-196a2 rs11614913 polymorphism increased the risk of NSCLC lung cancer. In addition, the results do not support an association between the genetic variant of miR-499 rs3746444 and the risk of developing lung cancer. Additional larger clinical studies together with an analysis of the related cell functional outcomes are required.

**Competing Interests**

The authors declare that they have no competing interests.

**Funding**

This study was supported by internal funding. EM is funded by the Iran National Science Foundation (INSF) grant number 98003666. IMA is supported by the EPSRC (EP/T003189/1 and EP/V052462/1), the UK MRC (MR/T010371/1 and MR/M016579/1) and the Wellcome Trust (208340/Z/17/Z).

**REFERENCES**

1. Travis WD. Pathology of lung cancer. *Clin Chest Med* 2002;23(1):65-81, viii.
2. Dezfuli NK, Adcock IM, Alipoor SD, Seyfi S, Salimi B, Mafi Golchin M, et al. The miR-146a SNP Rs2910164 and miR-155 SNP rs767649 are risk factors for non-small cell lung cancer in...
22 miR196a as a Risk Factors of Lung Cancer

3. Dezfuli NK, Alipoor SD, Dalil Roochoyee N, Seyfi S, Salimi B, Adcock IM, et al. Evaluation Expression of miR-146a and miR-155 in Non-Small-Cell Lung Cancer Patients. Front Oncol 2021;11:715677.
4. Mortaz E, Alipoor SD, Movassaghi M, Vaharam M, Ghorbani J, Folkerts G, et al. Water-pipe smoke condensate increases the internalization of Mycobacterium Bovis of type II alveolar epithelial cells (A549). BMC Pulm Med 2017;17(1):68.
5. Samet JM. Lung Cancer, Smoking, and Obesity: It's Complicated. J Natl Cancer Inst 2018;110(8):795-6.
6. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers 2015;1:15009.
7. Alipoor SD, Adcock IM, Garssen J, Mortaz E, Varahram M, Mirsaeidi M, et al. The roles of miRNAs as potential biomarkers in lung diseases. Eur J Pharmacol 2016;791:395-404.
8. Wilk G, Braun R. regQTLs: Single nucleotide polymorphisms that modulate microRNA regulation of gene expression in tumors. PLoS Genet 2018;14(12):e1007837.
9. Wu J, Jiang R. Prediction of deleterious nonsynonymous single-nucleotide polymorphism for human diseases. ScientificWorldJournal 2013;2013:675851.
10. Tak YG, Farnham PJ. Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. Epigenetics Chromatin 2015;8:57.
11. Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, Hemminki K, et al. Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetration alleles in German and Italian familial breast cancer cases. Hum Mutat 2010;31(1):E1052-7.
12. Chen P, Zhang J, Zhou F. miR-499 rs3746444 polymorphism is associated with cancer development among Asians and related to breast cancer susceptibility. Mol Biol Rep 2012;39(12):10433-8.
13. Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008;118(7):2600-8.
increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 2009;18(4):1183-7.

25. Yoon KA, Yoon H, Park S, Jang HJ, Zo JJ, Lee HS, et al. The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer. J Thorac Cardiovasc Surg 2012;144(4):794-807.

26. Hong MJ, Choi YY, Jang JA, Jung HJ, Lee SY, Lee WK, et al. Association between genetic variants in pre-microRNAs and survival of early-stage NSCLC. J Thorac Oncol 2013;8(6):703-10.

27. Qiu H, Xie Z, Tang W, Liu C, Wang Y, Gu H, et al. Association between microRNA-146a, -499a and -196a-2 SNPs and non-small cell lung cancer: a case-control study involving 2249 subjects. Biosci Rep 2021;41(2):BSR20201158.

28. Hong YS, Kang HJ, Kwak JY, Park BL, You CH, Kim YM, et al. Association between microRNA196a2 rs1164913 genotypes and the risk of non-small cell lung cancer in Korean population. J Prev Med Public Health 2011;44(3):125-30.

29. Vinci S, Gelmini S, Pratesi N, Conti S, Malentacchi F, Simi L, et al. Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem Lab Med 2012;49(12):2073-80.

30. Fan X, Wu Z. Effects of four single nucleotide polymorphisms in microRNA-coding genes on lung cancer risk. Tumour Biol 2014;35(11):10815-24.

31. Vaccari S, Gelmisi S, Pratesi N, Conti S, Malentacchi F, Simi L, et al. Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin Chem Lab Med 2011;49(12):2073-80.

32. Wang Y, Yang B, Ren X. Hsa-miR-499 polymorphism (rs3746444) and cancer risk: a meta-analysis of 17 case-control studies. PLoS One 2012;7(9):e65123.

33. Chen C, Yang S, Chaugai S, Wang Y, Wang DW. Meta-analysis of Hsa-miR-499 polymorphism (rs3746444) for cancer risk: evidence from 31 case-control studies. BMC Med Genet 2014;15:126.

34. Hashemi M, Moradi N, Ziaee SA, Narouie B, Soltani MH, Rezaei M, et al. Association between single nucleotide polymorphism in mir-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population. J Adv Res 2016;7(3):491-8.